PMA device
Resonate family of CRT-D's
Boston Scientific Corp · Defibrillator, Automatic Implantable Cardioverter, With Cardiac Resynchronization (Crt-D) (NIK, Class III) · First FDA decision Sep 20, 2017, newest Oct 7, 2021Heart failureVentricular arrhythmia and sudden cardiac arrest
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
3
Naming "Resonate"
MAUDE reports
6,620
Brand "Resonate", since 2015
PubMed studies
1,939
Mentioning "Resonate"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Resonate family of CRT-D's
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- Resonate family of CRT-D'sPMA supplement
P010012-S540 · Decided Oct 7, 2021 · 92 days after receipt · Normal 180 Day Track No User Fee
Device type: Defibrillator, automatic implantable cardioverter, with cardiac resynchronization (CRT-D) (NIK) · Cardiology
- Resonate, Momentum, Vigilant, Autogen, Dynagen, Inogen, Origen Cardiac Resynchronization Therapy DefibrillatorsPMA supplement
P010012-S528 · Decided Oct 7, 2021 · 329 days after receipt · Normal 180 Day Track
Device type: Defibrillator, automatic implantable cardioverter, with cardiac resynchronization (CRT-D) (NIK) · Cardiology
- Resonate, Momentum, Vigilant, Autogen, Dynagen, Inogen, and Origen Cardiac Resynchronization Therapy Defibrillators (CRTPMA supplement
P010012-S504 · Decided Jul 31, 2019 · 89 days after receipt · Normal 180 Day Track
Device type: Defibrillator, automatic implantable cardioverter, with cardiac resynchronization (CRT-D) (NIK) · Cardiology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Cardioverter DefibrillatorsNational analysisReview closedCAG-00157R4Updated Nov 19, 2026
- Implantable Cardioverter Defibrillators (ICDs)National determinationOn the books20.4Updated Sep 28, 2026
- Implantable Cardioverter Defibrillators (ICDs)National analysisReview closedCAG-00157NUpdated Sep 15, 2026
- Surveillance of Implantable or Wearable Cardioverter Defibrillators (ICDs): Office, Hospital, Web, or Non-Web BasedLocal determinationIn effectL34087CGS Administrators, LLCUpdated Aug 28, 2026
- Implantable DefibrillatorsNational analysisReview closedCAG-00157R2Updated Nov 19, 2026
- Wireless Stimulation Endocardially for Cardiac Resynchronization Therapy System (WiSE CRT)National analysisReview closedCAG-00471NUpdated Nov 18, 2026
- Implantable Defibrillators - Clinical TrialsNational analysisReview closedCAG-00157RUpdated Sep 15, 2026
- Implantable DefibrillatorsNational analysisReview closedCAG-00157R3Updated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Resonate", any status and sponsor, newest update first.
Virginia Commonwealth UniversityAcademic, hospital or other
NCT03883217 · 12 participants · Start Jun 29, 2021 · Primary completion Jan 11, 2022
Device: Vibration Session; No vibration session · For: Parkinson Disease
Sites: Richmond, Virginia
Virginia Commonwealth UniversityAcademic, hospital or other
NCT03872115 · 0 participants · Start Apr 18, 2019 · Primary completion Apr 2020
Device: PDVibe2 · For: Parkinson Disease
- Strategic Management to Improve CRT Using Multi-Site Pacing Post Approval Study (Reference # C1918)Completed
Boston Scientific CorporationPublic (BSX)
NCT03257436 · 586 participants · Start Jan 5, 2018 · Primary completion Nov 19, 2020
Device: CRT-D · For: Left Ventricular Dysfunction
Sites: Mobile, Alabama; Phoenix, Arizona; Jonesboro, Arkansas · 54 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Resonate", and for the whole product code for context.
This brand
6,620 reports: 3,043 malfunction, 3,528 injury, 49 death
Whole product code NIK
127,080 reports: 63,286 malfunction, 61,191 injury, 2,565 death
Newest reports for this brand
- RESONATE HF ICD DRInjury
2124215-2026-57837 · Received Oct 30, 2026 · Event dated Oct 9, 2026
Device type: Implantable Cardioverter Defibrillator (Non-Crt) (LWS)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Unspecified Infection
- RESONATE? HF ICD DRMalfunction
2124215-2026-57480 · Received Oct 29, 2026 · Event dated Oct 9, 2026
Device type: Implantable Cardioverter Defibrillator (Non-Crt) (LWS)
Device problem as coded: Signal Artifact/Noise; Over-Sensing; Pacing Problem; Inappropriate/Inadequate Shock/Stimulation
Patient problem as coded: Shock from Patient Lead(s)
- RESONATE X4 CRTDInjury
2124215-2026-57508 · Received Oct 29, 2026 · Event dated Oct 1, 2026
Device type: Defibrillator, Automatic Implantable Cardioverter, With Cardiac Resynchronization (Crt-D) (NIK)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Bacterial Infection
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1671-2022 · Started Jul 7, 2022
Reason given: There is potential for unanticipated software anomalies to occur when using the Model 2868 Application loaded on the 3120 ZOOM LATITUTDE programmer when communicating with certain Boston Scientific transvenous defibrillators.
Cause as FDA categorized it: Under Investigation by firm · Device type: Defibrillator, Automatic Implantable Cardioverter, With Cardiac Resynchronization (Crt-D) (NIK)
Z-0079-2018 · Started Oct 4, 2017
Reason given: The devices have an incorrect firmware configuration.
Cause as FDA categorized it: Under Investigation by firm · Device type: Defibrillator, Automatic Implantable Cardioverter, With Cardiac Resynchronization (Crt-D) (NIK)
- MOMENTUM X4 CRT-D, Model G138, Sterile.Terminated
Z-0080-2018 · Started Oct 4, 2017
Reason given: The devices have an incorrect firmware configuration.
Cause as FDA categorized it: Under Investigation by firm · Device type: Defibrillator, Automatic Implantable Cardioverter, With Cardiac Resynchronization (Crt-D) (NIK)
16 more recall records with a free account
Published research
The most relevant PubMed records for "Resonate"[tiab]. The summary above synthesizes these.
- Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Mato AR, Roeker LE, Allan JN, et al. · Am J Hematol · 2018Multicenter Study
- How far can ibrutinib resonate?
Guièze R · Blood · 2025Editorial, Comment
- Nurturing Engagement-Capable Environments.
Keresteci M, Lang A · Healthc Pap · 2024Editorial, Introductory Journal Article
- Empathy and compassion.
Singer T, Klimecki OM · Curr Biol · 2014
- The Nightingale Legacy.
Allen DH · Clin J Oncol Nurs · 2020Historical Article
- Resonate-and-fire neurons.
Izhikevich EM · Neural Netw · 2001Research Support, U.S. Gov't, Non-P.H.S., Review
- Dawid Lichosyt.
Lichosyt D · Angew Chem Int Ed Engl · 2025
- Florence Nightingale (1820-1910): The Founder of Modern Nursing.
Turkowski Y, Turkowski V · Cureus · 2024Review
- Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Barr PM, Owen C, Robak T, et al. · Blood Adv · 2022Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Transforming science communication through storytelling.
Guglielmi G, Petersen E, Alvarez L, et al. · FEBS Lett · 2024
- Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.
Burger JA, Barr PM, Robak T, et al. · Blood · 2025Randomized Controlled Trial, Clinical Trial, Phase III
Other devices of this type
Also filed under product code NIK.
- Amplia MRI CRT-DMedtronic Cardiac Rhythm Disease Management · PMA 2022
- Promote/+/RF/QAbbott Medical · PMA 2026
- Contak CDBoston Scientific Corp · PMA 2022
- Frontier/Frontier Ii/Anthem Family of Crt-PsAbbott Medical · PMA 2016
- Microny Family of PacemakersAbbott Medical · PMA 2016
- Sensolog/Dialog/Regency Family of PacemakersSt. Jude Medical, Inc. · PMA 2016
- Contak Cd,easytrakBoston Scientific Corp · PMA 2026
- Quadra Assura/Unify Assura Family of Crt-DsAbbott Medical · PMA 2016
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.